Skip to main content

Table 5 Questions and responses of radiotherapy-related details are grouped based on clinical experience among all respondents

From: Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China

Radiotherapy-related details

Clinical experience (years)---Responders N (%)

All (n=484)

1–5 (n=82)

6–10 (n=121)

11-20 (n=163)

≥ 21 (n=118)

Total dose

50 Gy

382 (78.9)

56 (68.3)

98 (81.0)

133 (81.6)

95 (80.5)

54 Gy

99 (20.5)

25 (30.5)

22 (18.2)

29 (17.8)

23 (19.5)

Others

3 (0.6)

1 (1.2)

1 (0.8)

1 (0.6)

0 (0.0)

Targeted region closest to clinical practicea

Lung stump + ipsilateral hilus + regions containing positive LNs

283 (58.5)

42 (51.2)

62 (51.2)

99 (60.7)

80 (67.8)

Lung stump + ipsilateral mediastinum ± ipsilateral supraclavicular LNsb

238 (49.3)

52 (63.4)

64 (52.9)

75 (46.3)

47 (39.8)

 Lung stump + ipsilateral mediastinum ± contralateral upper mediastinum c

132 (27.3)

22 (26.8)

26 (21.5)

49 (30.1)

35 (29.7)

Prophylactic radiotherapy for stumpa

Surgical margins were near to tumor margins

375 (77.5)

56 (68.3)

89 (73.6)

131(80.4)

99 (83.9)

Central type

214 (44.2)

27 (32.9)

51 (42.1)

76 (46.6)

60 (50.8)

Any condition

102 (21.1)

21 (25.6)

28 (23.1)

32 (19.6)

21 (17.8)

Lung V20

<20%

173 (35.7)

33 (40.2)

43 (35.5)

51 (31.3)

46 (39.0)

<25%

217 (44.8)

33 (40.2)

51 (42.1)

79 (48.5)

54 (45.8)

<30%

87 (18.0)

16 (19.5)

24 (19.8)

32 (19.6)

15 (12.7)

Others

7 (1.4)

0 (0.0)

3 (2.5)

1 (0.6)

3 (2.5)

Heart dose constraint a, c

No limitation

19 (3.9)

10 (12.2)

4 (3.3)

1 (0.6)

4 (3.4)

Yes, Heart V30

437 (90.3)

68 (82.9)

107 (88.4)

152 (93.3)

110 (93.2)

<30%

71 (14.7)

7 (8.5)

18 (14.9)

23 (14.1)

23 (20.9)

<35%

45 (9.3)

6 (7.3)

5 (4.1)

17 (11.2)

17 (15.5)

<40%

280 (57.9)

43 (52.4)

75 (62.0)

100 (65.8)

62 (56.4)

Other

41 (8.5)

12 (14.6)

9 (7.4)

12 (7.9)

8 (7.3)

Yes, Heart V40

244 (50.4)

30 (36.6)

60 (49.6)

89 (54.6)

65 (55.1)

<20%

14 (2.9)

1 (1.2)

4 (3.3)

3 (1.8)

6 (5.1)

<25%

13 (2.7)

2 (2.4)

1 (0.8)

6 (3.7)

4 (3.4)

<30%

207 (42.8)

26 (31.7)

53 (43.8)

76 (46.6)

52 (44.1)

Other

10 (2.1)

1 (1.2)

2 (1.7)

4 (2.5)

3 (2.5)

  1. LNs Lymph nodes, PD-L1 Programmed cell death ligand-1
  2. aMultiple selection
  3. bIf the tumor location is the upper lobe of lung and/or level 2 LN station involved
  4. cIf the tumor location is left lung